AESKUCARE Gluten-Related Point-Of-Care test for determination of gluten associated specific IgA (human)
Gluten related disorders (GRDs) emerging globally, presenting a wide variety of either intra and/or extra-intestinal symptoms. The widespread rise of gluten consumption as well as processed foods, makes GRDs related to gluten important for different and increasing parts of the world.
AESKUCARE Gluten-Related Disorders IgA is a near patient (point of care) in-vitro immunoassay intended for the qualitative and quantitative simultaneous measurement of human-specific IgA antibodies against tTG, tTG neo, mTG, mTG neo, DGP, gliadin, Frazer’s fraction, TG3, and total IgA in heparinized or Na-EDTA venous or capillary whole blood, plasma, or serum. sIgA concentrations can be determined quantitatively by using a separately available reader or qualitatively by the naked eye.
Coated Antigens:

• mTG neo (test row 2): Microbial transglutaminase (neo-epitopes)
• TG3 (test row 2): Transglutaminase 3 (human epidermal transglutaminase)
• tTG (test row 2): Human tissue transglutaminase
• tTG neo (test row 2): Human tissue transglutaminase (neo-epitopes)
• mTG (test row 3): Microbial transglutaminase
• Frazer's F (test row 3): Frazer's fraction
• Gliadin (test row 3): Alpha-gliadin
• DGP (test row 3): Deamidated gliadin-specific peptide